RAD-140 is a non-steroidal SARM with exceptionally high AR affinity (Ki ~7 nM). Distinguished from other SARMs by: (1) highest anabolic-to-androgenic ratio in its class (~90:1 vs testosterone), (2) partial AR antagonism in prostate tissue — actively reduces prostate weight in castrated rodent models. Also demonstrates neuroprotective activity via AR-mediated MAPK and PI3K/Akt signalling in neuronal cells — a mechanism distinct from its anabolic effects.
Also Known As
Testolone, RAD140
Compound Class
Selective androgen receptor modulator (SARM)
Molecular Formula
C₂₀H₁₆ClN₅O₂
Molecular Weight
393.83 Da
CAS Number
1182367-47-0
Half-Life
~60 hours (longest among common SARMs)
Research Applications
Muscle Anabolism Research
Castrated primate model (cynomolgus monkeys): RAD-140 restored lean body mass dose-dependently, comparable to testosterone propionate at lower doses. Prostate weight significantly lower than testosterone group at equivalent muscle dose. Strong preclinical anabolic profile.
Neuroprotection / Neurodegeneration
RAD-140 activates AR in hippocampal neurons, protecting against excitotoxic cell death and beta-amyloid-induced toxicity in primary culture models. MAPK signalling pathway activation independent of PI3K. Potential Alzheimer’s disease research application — unique among SARMs.
AR Antagonism in Prostate
Unlike LGD-4033 which is neutral in prostate, RAD-140 acts as AR antagonist in prostate cells — actively suppresses androgen-driven prostate growth. Research interest in hormone-sensitive prostate cancer models.
Breast Cancer Research
AR-positive, ER-positive breast cancer models: RAD-140 suppresses ER-driven proliferation via AR-mediated antagonism of ER signalling. Phase 2 trial data in AR+/ER+ metastatic breast cancer showing disease stabilisation.
Key Research Data
Study / Source
Key Findings
Bhola et al. 2021 Cancer Research
Phase 2: RAD-140 in AR+/ER+ metastatic breast cancer, clinical benefit rate 32%, disease stabilisation
Jayaraman et al. 2014 Endocrinology
Neuroprotective activity in vitro: RAD-140 protected hippocampal neurons from apoptosis, MAPK activation
Miller et al. 2011 Endocrinology
Cynomolgus primate study: muscle mass restoration comparable to testosterone, marked prostate weight advantage
Specifications
Format
Oral tablet — 10mg per tablet
Purity
≥99% HPLC
Identity
MS confirmed
Storage
Room temperature, away from moisture and light
Reconstitution
N/A — oral
Frequently Asked Questions
What is RAD-140 (Testolone)?
RAD-140 (Testolone) is a non-steroidal SARM with exceptionally high anabolic-to-androgenic ratio (~90:1). Distinguished by neuroprotective activity via hippocampal AR signalling and partial AR antagonism in prostate tissue. Used in muscle wasting, neuroprotection, and AR-positive breast cancer research models.
What makes RAD-140 different from other SARMs like LGD-4033?
RAD-140 has a longer half-life (~60h vs ~24-36h for LGD-4033), neuroprotective activity in neuronal models (unique among common SARMs), and acts as an AR antagonist in prostate — actively reducing prostate weight vs testosterone controls. LGD-4033 is prostate-neutral. RAD-140 also has Phase 2 breast cancer trial data.
How is RAD-140 used in breast cancer research?
AR-positive, ER-positive breast cancer models: RAD-140 antagonises oestrogen receptor-driven proliferation via AR signalling crosstalk. Phase 2 clinical trial (Radius Health) demonstrated clinical benefit rate of 32% and disease stabilisation in AR+/ER+ metastatic breast cancer patients.
Does QSC ship RAD-140 to the USA?
Yes. QSC RAD-140 is available with domestic USA shipping and ships to EU, UK, Canada, and Australia. Janoshik third-party COA confirming ≥99% HPLC purity and MS identity.
